Zymeworks Inc. (ZYME) fair value analysis
Nasdaq · Updated 2026-10-19
ZYME price how computed
Valuation status
Awaiting full valuationZYME's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once ZYME's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $25.03
- Sector
- Healthcare
- 12-month range
- $16.46–$31.05
- Market cap
- $1.78B
- From 52-week high
- -19.4%
- Shares outstanding
- 71.2M
- Rank in Healthcare by quality score
- #279 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Zymeworks Inc. is a clinical-stage biopharmaceutical company that develops engineered therapeutics based on its Azymetric platform technology, which is designed to create improved antibody-based treatments for cancer and other diseases. The company is headquartered in Vancouver, Canada and operates in the United States and international markets.
ZYME currently ranks #279 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.78B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $37.1M
- Net margin
- -404.0%
- EPS (TTM)
- $-2.02
- Gross margin
- 100.0%
- Debt / equity
- 3.34
- Revenue growth (3-yr avg)
- -24.1%
- Shares outstanding
- 71.2M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 40 · neutral
- 50-day average
- $26.75
- 200-day average
- $25.05
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▼ miss (-10.7%)
2026-03 ▼ miss (-490.0%)
2025-12 ▼ miss (-70.6%)
2025-09 ▲ beat (+18.8%)
2025-06 ▲ beat (+105.8%)
2025-03 ▲ beat (+57.1%)
2024-12 ▼ miss (-236.2%)
2024-09 ▲ beat (+4.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 14 buy · 0 hold · 0 sell (14 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $41.2
- Target vs last price
- +64.6%
What our data shows for ZYME
- Shares are trading in the middle of their 12-month price range of $16.46–$31.05.
- The 14-day relative strength index sits at a neutral 40.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ZYME's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ZYME news
TickrTrends' derived news-sentiment signal for ZYME is currently leaning positive, computed from recent coverage.
- Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma (manilatimes.net, 2026-10-19)
- Zymeworks Inc. (ZYME) M&A Call Transcript (seekingalpha.com, 2026-09-28)
- Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Eyes Growth in COPD Market (gurufocus.com, 2026-09-28)
More ZYME news
- Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - Slideshow (NASDAQ:ZYME) 2026-09-28 (seekingalpha.com, 2026-09-28)
What people are saying
Follow the ZYME conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — # ZYME Weekly Indicator Summary TickrTrends' derived indicators for ZYME show a shift in trend momentum this week. The 50/200-day trend state has moved from uptrend to mixed, reflecting changing price dynamics in the Healthcare sector stock. The valuation assessment remains awaiting full valuation.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ZYME stock undervalued?
ZYME's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is ZYME's TickrTrends verdict?
ZYME is currently marked 'Awaiting full valuation' - a verdict publishes automatically once ZYME's own trailing P/E history validates under our standards.
How does ZYME compare to other Healthcare stocks?
ZYME ranks #279 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ZYME overbought or oversold?
ZYME's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ZYME report earnings next?
ZYME's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does ZYME usually beat earnings estimates?
Over its last 8 reported quarters ZYME beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ZYME?
Of 14 analysts covering ZYME, 14 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $41.2 (+64.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.